About PHD finger protein 24
PHD finger protein 24 (PHF24) is a protein
from Homo sapiens identified by UniProt accession
Q9UPV7, 400 residues long.
MolForge cross-references it against 0 known binders and
39 disease associations.
Target properties
| Protein name | PHD finger protein 24 |
|---|
| UniProt accession | Q9UPV7 |
|---|
| Gene | PHF24 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 400 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (39)
Diseases linked to this target (Open Targets).
- breast ductal adenocarcinoma · score 0.11
- platelet count · score 0.08
- psoriasis · score 0.07
- eosinophil percentage of leukocytes · score 0.07
- platelet crit · score 0.06
- eosinophil count · score 0.05
- myeloid white cell count · score 0.05
- mean corpuscular volume · score 0.05
- glioblastoma multiforme · score 0.04
- neutrophil count · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UPV7-F1 | alphafold | PREDICTED | 73.26 | — |
Amino-acid sequence (400 residues)
MGVLMSKRQT VEQVQKVSLA VSAFKDGLRD RPSIRRTGEL PGSRRGTVEG SVQEVQEEKE AEAGTSVVQE ESSAGRAAWE RLRDGRGVEP EEFDRTSRFT PPAFIRPTRK LDDDKPPEIC LEPREPVVND EMCDVCEVWT AESLFPCRVC TRVFHDGCLR RMGYIQGDSA AEVTEMAHTE TGWSCHYCDN INLLLTEEEM YSLTETFQRC KVIPDCSLTL EDFLRYRHQA AKRGDRDRAL SEEQEEQAAR QFAALDPEHR GHIEWPDFLS HESLLLLQQL RPQNSLLRLL TVKERERARA AFLARGSGST VSEAECRRAQ HSWFCKRFPE APSCSVSISH VGPIADSSPA SSSSKSQDKT LLPTEQESRF VDWPTFLQEN VLYILAARPN SAAIHLKPPG
Explore PHD finger protein 24 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets